These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30797147)

  • 1. Potential roles of 5-HT
    Zulkifli MH; Viswenaden P; Jasamai M; Azmi N; Yaakob NS
    Biomed Pharmacother; 2019 Apr; 112():108630. PubMed ID: 30797147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis.
    Rojas C; Raje M; Tsukamoto T; Slusher BS
    Eur J Pharmacol; 2014 Jan; 722():26-37. PubMed ID: 24184669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.
    Kishi T; Mukai T; Matsuda Y; Iwata N
    Neuromolecular Med; 2014 Mar; 16(1):61-9. PubMed ID: 23896722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Binding of Palonosetron and Other Antiemetic Drugs to the Serotonin 5-HT3 Receptor.
    Zarkadas E; Zhang H; Cai W; Effantin G; Perot J; Neyton J; Chipot C; Schoehn G; Dehez F; Nury H
    Structure; 2020 Oct; 28(10):1131-1140.e4. PubMed ID: 32726573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic action of 5-HT3 receptor antagonists targeting peritoneal macrophages in post-operative ileus.
    Maehara T; Matsumoto K; Horiguchi K; Kondo M; Iino S; Horie S; Murata T; Tsubone H; Shimada S; Ozaki H; Hori M
    Br J Pharmacol; 2015 Feb; 172(4):1136-47. PubMed ID: 25377620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor.
    Rojas C; Stathis M; Thomas AG; Massuda EB; Alt J; Zhang J; Rubenstein E; Sebastiani S; Cantoreggi S; Snyder SH; Slusher B
    Anesth Analg; 2008 Aug; 107(2):469-78. PubMed ID: 18633025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interaction of trichloroethanol with murine recombinant 5-HT3 receptors.
    Downie DL; Hope AG; Belelli D; Lambert JJ; Peters JA; Bentley KR; Steward LJ; Chen CY; Barnes NM
    Br J Pharmacol; 1995 Apr; 114(8):1641-51. PubMed ID: 7541281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local-anesthetic like inhibition of the cardiac sodium channel Nav1.5 α-subunit by 5-HT3 receptor antagonists.
    Van't Klooster MP; Foadi N; Hage A; Stoetzer C; Wegner F; Eberhardt M; Leffler A
    Eur J Pharmacol; 2016 Oct; 789():119-126. PubMed ID: 27401036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
    Billio A; Morello E; Clarke MJ
    Cochrane Database Syst Rev; 2010 Jan; (1):CD006272. PubMed ID: 20091591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agonists and antagonists induce different palonosetron dissociation rates in 5-HT₃A and 5-HT₃AB receptors.
    Lummis SC; Thompson AJ
    Neuropharmacology; 2013 Oct; 73():241-6. PubMed ID: 23747573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palonosetron-5-HT
    Price KL; Lillestol RK; Ulens C; Lummis SC
    ACS Chem Neurosci; 2016 Dec; 7(12):1641-1646. PubMed ID: 27656911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT
    Zajdel P; Grychowska K; Mogilski S; Kurczab R; Satała G; Bugno R; Kos T; Gołębiowska J; Malikowska-Racia N; Nikiforuk A; Chaumont-Dubel S; Bantreil X; Pawłowski M; Martinez J; Subra G; Lamaty F; Marin P; Bojarski AJ; Popik P
    J Med Chem; 2021 Sep; 64(18):13279-13298. PubMed ID: 34467765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.
    Machu TK
    Pharmacol Ther; 2011 Jun; 130(3):338-47. PubMed ID: 21356241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Roles of 5-HT
    Satiamurthy R; Yaakob NS; Shah NM; Azmi N; Omar MS
    Curr Mol Med; 2023; 23(4):341-349. PubMed ID: 35549869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should palonosetron be a preferred 5-HT
    Chow R; Warr DG; Navari RM; Tsao M; Popovic M; Chiu L; Milakovic M; Lam H; DeAngelis C
    Support Care Cancer; 2018 Aug; 26(8):2519-2549. PubMed ID: 29796708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting.
    Rojas C; Slusher BS
    Eur J Pharmacol; 2012 Jun; 684(1-3):1-7. PubMed ID: 22425650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis.
    Tricco AC; Blondal E; Veroniki AA; Soobiah C; Vafaei A; Ivory J; Strifler L; Cardoso R; Reynen E; Nincic V; Ashoor H; Ho J; Ng C; Johnson C; Lillie E; Antony J; Roberts DJ; Hemmelgarn BR; Straus SE
    BMC Med; 2016 Dec; 14(1):216. PubMed ID: 28007031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged inhibition of 5-HT₃ receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization.
    Hothersall JD; Moffat C; Connolly CN
    Br J Pharmacol; 2013 Jul; 169(6):1252-62. PubMed ID: 23581504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolongation of bronchopulmonary C-fiber-mediated apnea by prenatal nicotinic exposure in rat pups: role of 5-HT
    Zhao L; Gao X; Zhuang J; Wallen M; Leng S; Xu F
    FASEB J; 2019 Oct; 33(10):10731-10741. PubMed ID: 31251077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and Pharmacological Evaluation of [
    Mu L; Müller Herde A; Rüefli PM; Sladojevich F; Milicevic Sephton S; Krämer SD; Thompson AJ; Schibli R; Ametamey SM; Lochner M
    ACS Chem Neurosci; 2016 Nov; 7(11):1552-1564. PubMed ID: 27571447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.